USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
16 May 2023 | 02:45 PM GMT

Role Of Digital Health Across Brand Life Cycle In Pharma

Anchored by:

Till Bauer
Global Oncology LCM Strategy Director
MSD

Participants:

Till Bauer Global Oncology LCM Strategy DirectorMSD
Till Bauer
Global Oncology LCM Strategy DirectorMSD
Melinda Decker AdvisorPlexus Ventures
Melinda Decker
AdvisorPlexus Ventures
Ashley Pippin DirectorNovartis
Ashley Pippin
DirectorNovartis
Elisabeth Tsechanski Digital Innovation HubDaiichi Sankyo Europe
Elisabeth Tsechanski
Digital Innovation HubDaiichi Sankyo Europe
Katie Cannon Director - Strategic PartnershipsAvegen Health
Katie Cannon
Director - Strategic PartnershipsAvegen Health
Marta Sole Venture Innovation ManagerMon Clinic
Marta Sole
Venture Innovation ManagerMon Clinic
Mitesh Daftardar Digital Innovation Hub LeadMerz Therapeutics
Mitesh Daftardar
Digital Innovation Hub LeadMerz Therapeutics
Sonali Agarwal Senior Manager, Digital Health & InnovationGlaxoSmithKline
Sonali Agarwal
Senior Manager, Digital Health & InnovationGlaxoSmithKline
Steffanie Bristol Head, Biogen Digital Health VenturesBiogen
Steffanie Bristol
Head, Biogen Digital Health VenturesBiogen
Weronika Michaluk MedTech Practice LeadHTD Health
Weronika Michaluk
MedTech Practice LeadHTD Health

About this Meeting

Small, intimate and participant-led discussions tackling digital health challenges. Spaces are limited to 8 - 12 people, allowing you to focus on quality in-depth conversations.

Throughout each phase of a drug's life cycle, it is crucial to optimise both clinical and product value: from pre-launch and launch, to growth, maturity, and eventual decline. Digital solutions can play a vital role in enhancing brand strategy, but their importance varies depending on the stage of the brand's lifecycle. So, where do digital solutions fit into your strategy? Join our conversation to discuss the role of digital solutions at different stages of the drug life cycle, according to the phase your brand strategy is currently in. We'll explore how to use digital solutions to optimise clinical and product value and focus on the following:
  • Opportunities for digital health solutions within pharma’s brand strategies. What are the opportunities for digital health solutions in pharma’s brand strategy? From pre-launch to patient activation, where can digital add the most value and how can you set up your brand for success with digital health solutions.
  • How to leverage digital solutions across the brand lifecycle. Should digital solutions be considered only at a launch stage? How can growth-stage and mature-stage brands evaluate digital health solutions? Are there digital health solutions that are more suitable for specific stages in the life cycle and if so, how can understanding the brand's life cycle stage inform the selection of appropriate digital health solutions?
  • Challenges with adopting and implementing digital health solutions into drug brand strategies. What are the primary challenges with digital health solutions faced by brand and commercial teams? How can different teams collaborate to overcome these challenges?
We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.